Haemophilus influenzae Type b-Outer Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal Immunogenicity

Journal of Immunology

Volumn 172, Issue 4, 2004, Pages 2431-2438

  Latz, Eicke ^a   Franko, Jennifer ^b,c   Golenbock, Douglas T ^a   Schreiber, John R ^b,c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CYTOKINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELOID DIFFERENTIATION FACTOR 88; OUTER MEMBRANE PROTEIN; PROTEIN CRM 197; TETANUS TOXOID; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG CONJUGATION; DRUG PROTEIN BINDING; EMBRYO; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; KNOCKOUT MOUSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE;

EID: 0842300354     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.4.2431     Document Type: Article

References (36)

1. Mond, J. J., A. Lees, and C. M. Snapper. 1995. T cell-independent antigens type 2. Annu. Rev. Immunol. 13:65.
2. Stein, K. E. 1992. Thymus-independent and thymus-dependent responses to polysaccharide antigens. J. Infect. Dis. 16:S49.
3. Kaythy, H., Y. Karanko, H. Peltola, and P. H. Makela. 1984. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to re-immunization: no evidence of immunological tolerance or memory. Pediatrics 74:857.
4. Cowan, M. J., A. J. Ammann, D. W. Wara, V. M. Howie, L. Schultz, N. Doyle, and M. Kaplan. 1978. Pneumococcal polysaccharide immunization in infants and children. Pediatrics 62:721.
5. Douglas, R. M., J. C. Paton, S. J. Duncan, and D. J. Hansman. 1983. Antibody response to pneumococcal vaccination in children younger than five years of age. J. Infect. Dis. 148:131.
6. Smith, D. H., G. Peter, D. L. Ingram, A. L. Harding, and P. Anderson. 1973. Responses of children immunized with the capsular polysaccharide of Haemophilus influenzae type b. Pediatrics 52:637.
7. Black, S. B., H. R. Shinefield, B. Fireman, M. Hiatt, M. Polen, and E. Vittinghoff. 1991. Efficacy in infancy of oligosaccharide Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr. Infect. Dis. 10:97.
8. Black, S. B., H. R. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring, J. Noyes, E. Lewis, P. Ray, J. Lee, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810.
9. 197 in United States infants. Pediatrics. 101:604.
10. Guttormsen, H. K., A. H. Sharpe, A. K. Chandraker, A. K. Brigtsen, M. H. Sayegh, and D. L. Kasper. 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375.
11. st century: global analysis of the disease burden 25 years after the use of polysaccharide vaccine and a decade after the advent of conjugates. Clin. Microbiol. Rev. 13:302.
12. Donnelly, J. J., R. R. Deck, and M. A. Liu. 1990. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseriae meningitidis outer membrane protein vaccine. J. Immunol. 143:3071.
13. Granoff, D. M., and S. J. Holmes. 1991. Comparative immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines. Vaccine 9:S30.
14. Galil, K., R. Singleton, O. S. Levine, M. A. Fitzgerald, L. Bulkow, M. Getty, B. A. Perkins, and A. Parkinson. 1999. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J. Infect. Dis. 179:101.
15. Ambrosino, D. M., D. Bolon, H. Collard, R. Van Etten, M. V. Kanchana, and R. W. Finberg. 1992. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages. J. Immunol. 149:3978.
16. Wetzler, L. M., Y. Ho, and H. Reiser. 1996. Neisserial porins induce B lymphocytes to express costimulatory B7-2 molecules and to proliferate. J. Exp. Med. 183:1151.
17. Massari, P., P. Henneke, Y. Ho, E. Latz, D. Golenbock, and L. Wetzler. 2002. Immune stimulation by neisserial porins is toll-like receptor 2 and Myd88 dependent. J. Immunol. 168:1533.
18. Hirschfeld, M., Y. Ma, J. H. Weis, S. N. Vogel, and J. J. Weis. 2000. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine Toll-like receptor 2. J. Immunol. 165:618.
19. Flo, T. H., O. Halaas, E. Lien, L. Ryan, G. Teti, D. T. Golenbock, A. Sundan, and T. Espevik. 2000. Human toll-like receptor 2 mediates monocyte activation by Listeria monocytogenes, but not by group B streptococci or lipopolysaccharide. J. Immunol. 164:2064.
20. Mullarkey, M., J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S. Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, et al. 2003. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304:1093.
21. Latz, E., A. Visintin, E. Lien, K. A. Fitzgerald, B. G. Monks, E. A. Kurt-Jones, D. T. Golenbock, and T. Espevik. 2002. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the Toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277:47834.
22. Visintin, A., A. Mazzoni, J. A. Spitzer, and D. M. Segal. 2001. Secreted MD-2 is a large polymeric protein that efficiently confers lipopolysaccharide sensitivity to toll-like receptor 4. Proc. Natl. Acad. Sci. USA 98:12156.
23. Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi, and S. Akira. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 9:143.
24. Takeuchi, O., K. Hoshino, and S. Akira. 2000. Cutting edge: TLR2-deficient mice and MyD88-deficient mice are highly susceptible to Staphlococcus aureus infection. J. Immunol. 165:5392.
25. Phipps, D. C., J. West, R. Eby, M. Koster, D. V. Madore, and S. A. Quataert. 1990. An ELISA employing Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen-binding assay. J. Immunol. Methods 135:121.
26. + T cell cytokine response that correlates with the isotype of antipolysaccharide antibody. J. Infect. Dis. 184:931.
27. 197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein. J. Infect. Dis. 187:1629.
28. Wetzler, L. M. 1994. Immunopotentiating ability of neisserial outer membrane proteins: use as an adjuvant for poorly immunogenic substances and potential use as vaccines. Ann. NY Acad. Sci. 730:367.
29. Hirano, T., K. Yasukawa, H. Harada, T. Taga, Y. Watanabe, T. Matsuda, S. Kashiwamura, K. Nakajima, K. Koyama, A. Iwamatsu, et al. 1986. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73.
30. + T cells. J. Exp. Med. 166:461.
31. Pulendran, B., P. Kumar, C. W. Cutler, M. Mohamadzadeh, T. Van Dyke, and J Banchereau. 2001. Lipopolysaccharides from distinct pathogens induce different classes of immune responses in vivo. J. Immunol. 167:5067.
32. Sieling, P. A., W. Chung, B. T. Duong, P. J. Godowski, and R. L. Modlin. 2003. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J. Immunol. 170:194.
33. Alexopoulou, L., V. Thomas, M. Schnare, Y. Lobet, J. Anguita, R. T. Schoen, R. Medzhitov, E. Fikrig, and R. A. Flavell. 2002. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1 and TLR2-deficient mice. Nat. Med. 8:878.
34. Takeuchi, O., S. Sato, T. Horiuchi, K. Hoshino, K. Takeda, Z. Dong, R. L. Modlin, and S. Akira. 2002. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169:10.
35. Takeuchi, O., T. Kawai, P. F. Muhlradt, M. Morr, J. D. Radolf, A. Zychlinsky, K. Takeda, and S. Akira. 2001. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13:933.
36. + T cells and could be an efficient vaccine target. J. Immunol. 171:32.